Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren alone and with hydrochlorothiazide in essential hypertension
2004-000240-25Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren and hydrochlorothiazide in essential hypertension (4 arms), sponsored by Novartis. Primary endpoints: Change from baseline in mean sitting diastolic blood pressure and Change from baseline in mean sitting systolic blood pressure. Started Jun 2004; status: completed.
02
Drugs
aliskirenhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2004-000240-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000240-25.